AnaptysBio (ANAB)

• Market cap: $1.47B
• 1 day: -3.32%
• 5 days: 6.42%
• 1 month: 10.28%
• 3 months: 59.59%
• 6 months: 156.18%
• Year to date: 18.09%
• 1 year: 175.17%
• 5 years: 65%
• 10 years: 212.24%
• Sector: Healthcare
• Industry: Biotechnology

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 136